This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth to Curtail Medicare Advantage Costs: Margin Boost Ahead?
by Zacks Equity Research
UNH's CEO pledges reform after rare earnings miss as rising Medicare Advantage costs squeeze margins and spook investors.
UnitedHealth Declines 40.4% YTD: Here's Why it's Still Not a Bargain
by Kaibalya Pravo Dey
UNH shares have plunged YTD, but regulatory risks, cost pressures and earnings downgrades keep it far from a bargain.
Humana (HUM) Down 10.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
by Kaibalya Pravo Dey
Strong capital efficiency and commercial growth make ELV appealing, but regulatory and cost headwinds keep investors cautious.
UnitedHealth Spirals Downward Amid New Criminal Probe: Time to Sell?
by Kaibalya Pravo Dey
UNH's troubles are piling up, from a fresh DOJ criminal probe and rising costs to leadership shakeups and pulled guidance.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Humana's Q1 Earnings Beat Estimates on CenterWell Segment Strength
by Zacks Equity Research
HUM's first-quarter results reflect higher primary care revenues and a well-performing Medicare stand-alone PDP business, partly offset by elevated operating costs.
CNC vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNC vs. HUM: Which Stock Is the Better Value Option?
Humana (HUM) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 16.03% and 0.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
by Zacks Equity Research
HUM's first-quarter results are likely to benefit from higher Medicare stand-alone PDP revenues.
Stay Ahead of the Game With Humana (HUM) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Humana (HUM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Earnings Preview: Cigna (CI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Shaken as UnitedHealth Tanks Since Q1 Miss: Buy the Dip?
by Kaibalya Pravo Dey
From a valuation perspective, UNH appears expensive compared to its peers despite the drop in price.
Humana (HUM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Healthcare ETFs Tug of War: Insurers Tumble, Pharma Surges
by Sanghamitra Saha
Healthcare ETFs split as insurers stumble and pharma surges -- highlighting the necessity of smart industry picks.
UnitedHealth Group (UNH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of -0.96% and 1.40%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
How Should You Play UnitedHealth Stock Going Into Q1 Earnings?
by Kaibalya Pravo Dey
UNH's first-quarter earnings are likely to have benefited from growing premiums and service revenues.
UnitedHealth vs. Humana: Which Healthcare Stock Should You Buy Now?
by Kaibalya Pravo Dey
The CMS announced a hike in MA payments for fiscal year 2026, which will likely deliver a notable boost to UNH & HUM's bottom lines.
Humana (HUM) Surges 10.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Markets Reverse Direction as Tariff Ante Upped on China
by Mark Vickery
An additional +50% tariffs on Chinese imports are now getting levied as of midnight tonight.
Strength Seen in Centene (CNC): Can Its 5.9% Jump Turn into More Strength?
by Zacks Equity Research
Centene (CNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks Industry Outlook Highlights UnitedHealth, Humana and Centene
by Zacks Equity Research
UnitedHealth, Humana and Centene are part of the Zacks Industry Outlook article.
3 HMO Stocks to Watch Amid Nurse Shortages, High Tech Costs
by Debasmita Chatterjee
The Medical-HMO industry rides on steady premium flows resulting from a growing customer base and contract wins. However, industry headwinds like elevated technology costs and workforce shortages remain concerns. UNH, HUM and CNC are likely to navigate industry storms.